



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, United States

Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 10132

Title: GW4064, an FXR agonist, upregulates adipokine expression in preadipocytes and HepG2 cells

Reviewer code: 02530654

Science editor: Ya-Juan Ma

Date sent for review: 2014-03-15 23:07

Date reviewed: 2014-04-23 21:48

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> [Y] Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> [Y] Grade B: minor language polishing	<input type="checkbox"/> [] Existed	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [Y] Grade C (Good)	<input type="checkbox"/> [] Grade C: a great deal of language polishing	<input type="checkbox"/> [] No records	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D (Fair)	<input type="checkbox"/> [] Grade D: rejected	BPG Search:	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E (Poor)		<input type="checkbox"/> [] Existed	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> [] No records	

COMMENTS TO AUTHORS

Concerns regarding the article: GW4064, an FXR agonist, upregulates adipokine expression in preadipocytes and HepG2 cells. Major concerns: 1) In the abstract, the mention conclusion of the work is a repeat of the results and should be omitted. 2) The introduction helps in understanding the pathogenesis and symptoms of NAFLD and NASH, however there is a certain lack of knowledge in the role of adiponectin, leptin and resistin in the above mentioned liver conditions. This should be clearly indicated as it will tie up the studies between adipocytes and liver cells. Has there been any studies on the adipokines issued from fatty liver in humans or animal models? 3) While the authors aim to find out a therapeutic approach for NAFLD from this study, there is no mention of any other therapies that are currently being used or the lack of it. 4) There is no justification provided for using different time points for the in-vitro experiments. While 3T3L1 is treated once at day 0, HepG2 cells are treated at an interval of 12 hours for 48 hours. 4) Any published reference indicating stable expression of GAPDH. Or else other reference genes should be included and used for normalization of the qPCR data. 5) Figure 3 B shows a significant difference between 0 hrs and 12 hrs which is not clear from the graph. Visually, due the SE bar, they don't look significant different. 6) While there is a justification provided for using 3T3L1 cells in discussion, there is no mention of HepG2 cells. Authors should also justify the selection of HepG2 cell model over others. The Minor concerns: 1) There is a scope for the introduction to be shortened that will make it easier for readers to focus on the issues. 2) Use of punctuation marks and space after each word needs to be checked. 3) et al vs et al., should be checked.